[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation].

We compared efficacy and safety of warfarin with those of direct thrombin inhibitor dabigatran, factor Xa inhibitors rivaroxaban and apixaban used for stroke prevention in 280 patients aged 65-80 years with non-valvular atrial fibrillation. Treatment for two years with dabigatran (110 mg twice daily), apixaban (5 mg twice daily) or rivaroxaban (20 mg/day) prevented strokes no less successfully than warfarin, but more rarely caused severe intracranial hemorrhages. When selecting antithrombotic therapy in geriatric patients with non-valvular AF new oral anticoagulants may be regarded as an acceptable alternative to warfarin.